Survodutide
Survodutide (GLP-1 / Glucagon Dual Agonist)
The liver-fat dual
An investigational GLP-1 and glucagon receptor dual agonist from Boehringer Ingelheim and Zealand Pharma. Like retatrutide it recruits the glucagon arm for energy expenditure, but its standout signal is in the liver — survodutide has produced striking reductions in liver fat and MASH (fatty liver disease), making it the incretin of interest for people with a visceral/metabolic-liver phenotype. In Phase 3 SYNCHRONIZE; not approved.
Key Benefits
Strong liver-fat reduction and MASH resolution in trials
GLP-1 + glucagon dual mechanism with energy-expenditure boost
Particularly relevant to a visceral / fatty-liver metabolic phenotype
Meaningful Phase 2 weight loss (below tirzepatide/retatrutide magnitude)
Once-weekly subcutaneous dosing
Mechanism of Action
How Survodutide works
Survodutide pairs appetite suppression with metabolic burn, weighted toward the liver:
- GLP-1 receptor agonism — central appetite reduction, delayed gastric emptying and glucose-dependent insulin release
- Glucagon (GCGR) receptor agonism — raises energy expenditure and, importantly, drives hepatic fat oxidation, which is why its liver-fat data stand out
- MASH/liver-fat reduction — in trials a majority of patients achieved MASH resolution, a result that distinguishes survodutide from weight-loss-only incretins
- No GIP arm — unlike tirzepatide or retatrutide, survodutide does not touch the GIP receptor, so GIPR genetics are not relevant to its response
Your Genetics & Survodutide
Genetic variants that affect your response
These SNPs determine how effectively Survodutide works for you specifically. A genetic peptide report identifies your variants before you start.
The glucagon arm is survodutide's differentiator — energy expenditure and hepatic fat oxidation. The Gly40Ser GCGR variant alters glucagon-receptor function, so it's the most mechanism-relevant gene for this drug, and irrelevant to GLP-1-only agents.
IRS1 variants associate with insulin resistance and a visceral-fat-prone metabolic background — exactly the phenotype survodutide's liver-targeting mechanism is built for.
Higher genetic set-point and appetite drive. As with all incretins, the case for a high-efficacy agent strengthens with a higher set-point.
T-allele carriers have blunted insulin secretion; the GLP-1 arm of survodutide can partly compensate for this beta-cell load.
Which variants do you carry?
Upload your DNA data or order a kit to find out.
Evidence & Research
14+
Published studies
Animal studies and in vitro data with promising but limited clinical validation
Common Stacks
Survodutide is commonly combined with:
Frequently Asked Questions
What is survodutide used for?
Survodutide is an investigational GLP-1/glucagon dual agonist studied for weight management and, notably, fatty liver disease (MASH). Its glucagon arm drives energy expenditure and hepatic fat burning, making it especially relevant for people with a visceral/metabolic-liver phenotype.
How is it different from retatrutide?
Both use the glucagon arm, but retatrutide is a triple agonist (it adds GIP), while survodutide is a GLP-1/glucagon dual with no GIP. Survodutide's clearest distinction is its liver-fat and MASH-resolution data.
Is survodutide approved?
No. As of 2026 survodutide is investigational, in the Phase 3 SYNCHRONIZE programme. It is not an available prescription.
Learn More About Survodutide
Your next move
Two ways forward with Survodutide.
Not sure it's for you?
Will Survodutide work for your genes — and at what dose?
Your report scores Survodutide against your receptor, CYP and pathway variants — likely responder, non-responder, and a sensible starting dose — in minutes.
Analyze my DNA — $99